A number of other equities research analysts have also recently weighed in on TRVN. Zacks Investment Research cut shares of Trevena from a buy rating to a hold rating in a report on Wednesday, May 15th. HC Wainwright set a $4.00 price objective on shares of Trevena and gave the stock a buy rating in a report on Monday, June 24th. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The company presently has a consensus rating of Hold and a consensus target price of $5.38.
TRVN traded down $0.02 during midday trading on Thursday, reaching $0.89. The company’s stock had a trading volume of 80,838 shares, compared to its average volume of 484,167. The company has a market capitalization of $84.03 million, a price-to-earnings ratio of -2.11 and a beta of 2.42. The company has a debt-to-equity ratio of 0.18, a current ratio of 3.58 and a quick ratio of 3.58. Trevena has a 1 year low of $0.38 and a 1 year high of $3.58. The company’s 50-day simple moving average is $1.01.
A number of institutional investors and hedge funds have recently made changes to their positions in the business. Two Sigma Advisers LP lifted its stake in shares of Trevena by 35.3% in the fourth quarter. Two Sigma Advisers LP now owns 62,900 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 16,400 shares in the last quarter. Alpine Global Management LLC bought a new position in shares of Trevena in the first quarter worth approximately $31,000. Geode Capital Management LLC lifted its stake in shares of Trevena by 38.9% in the fourth quarter. Geode Capital Management LLC now owns 477,007 shares of the biopharmaceutical company’s stock worth $205,000 after buying an additional 133,510 shares in the last quarter. Finally, Tibra Equities Europe Ltd bought a new position in shares of Trevena in the first quarter worth approximately $283,000. Institutional investors and hedge funds own 23.58% of the company’s stock.
Trevena Company Profile
Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of treatment options that target and treat diseases affecting the central nervous system. Its product candidates include Oliceridine injection, a G protein biased mu-opioid receptor (MOR) ligand that has completed Phase III clinical trials for the management of moderate-to-severe acute pain where intravenous administration is warranted; TRV250, a G protein biased delta- opioid receptor ligand, which is in Phase I clinical study for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR that has completed Phase I clinical study for the treatment of moderate-to-severe acute and chronic pain; TRV027 for the treatment of acute heart failure; and TRV045, a novel S1P modulator for managing chronic pain.
Further Reading: Trading Ex-Dividend Strategy
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.